161 related articles for article (PubMed ID: 22719187)
1. Transepithelial leak in Barrett's esophagus patients: the role of proton pump inhibitors.
Farrell C; Morgan M; Tully O; Wolov K; Kearney K; Ngo B; Mercogliano G; Thornton JJ; Valenzano MC; Mullin JM
World J Gastroenterol; 2012 Jun; 18(22):2793-7. PubMed ID: 22719187
[TBL] [Abstract][Full Text] [Related]
2. Transepithelial leak in Barrett's esophagus.
Mullin JM; Valenzano MC; Trembeth S; Allegretti PD; Verrecchio JJ; Schmidt JD; Jain V; Meddings JB; Mercogliano G; Thornton JJ
Dig Dis Sci; 2006 Dec; 51(12):2326-36. PubMed ID: 17103306
[TBL] [Abstract][Full Text] [Related]
3. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
Obszynska JA; Atherfold PA; Nanji M; Glancy D; Santander S; Graham TA; Otto WR; West K; Harrison RF; Jankowski JA
Gut; 2010 Feb; 59(2):156-63. PubMed ID: 19651631
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
5. Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication.
Bright T; Watson DI; Tam W; Game PA; Ackroyd R; Devitt PG; Schoeman MN
Dig Dis Sci; 2009 Dec; 54(12):2606-11. PubMed ID: 19101798
[TBL] [Abstract][Full Text] [Related]
6. The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.
Watson JT; Moawad FJ; Veerappan GR; Bassett JT; Maydonovitch CL; Horwhat JD; Wong RK
Dig Dis Sci; 2013 Aug; 58(8):2253-60. PubMed ID: 23824407
[TBL] [Abstract][Full Text] [Related]
7. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
8. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
9. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
Spechler SJ
Dig Dis; 2014; 32(1-2):156-63. PubMed ID: 24603402
[TBL] [Abstract][Full Text] [Related]
10. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.
Peng S; Huo X; Rezaei D; Zhang Q; Zhang X; Yu C; Asanuma K; Cheng E; Pham TH; Wang DH; Chen M; Souza RF; Spechler SJ
Am J Physiol Gastrointest Liver Physiol; 2014 Jul; 307(2):G129-39. PubMed ID: 24852569
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
12. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Akın H; Aydın Y
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
[TBL] [Abstract][Full Text] [Related]
13. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.
Jankowski JAZ; de Caestecker J; Love SB; Reilly G; Watson P; Sanders S; Ang Y; Morris D; Bhandari P; Brooks C; Attwood S; Harrison R; Barr H; Moayyedi P;
Lancet; 2018 Aug; 392(10145):400-408. PubMed ID: 30057104
[TBL] [Abstract][Full Text] [Related]
15. Squamous islands in Barrett's esophagus: what lies underneath?
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1998 Mar; 93(3):332-5. PubMed ID: 9517634
[TBL] [Abstract][Full Text] [Related]
16. Barrett's esophagus: proton pump inhibitors and chemoprevention II.
Richter JE; Penagini R; Tenca A; Pohl D; Dvorak K; Goldman A; Savarino E; Zentilin P; Savarino V; Watson JT; Wong RK; Pace F; Casini V; Peura DA; Herzig SJ; Kamiya T; Pelosini I; Scarpignato C; Armstrong D; DeVault KR; Bechi P; Taddei A; Freschi G; Ringressi MN; Degli'Innocenti DR; Castiglione F; Masini E; Hunt RH
Ann N Y Acad Sci; 2011 Sep; 1232():114-39. PubMed ID: 21950810
[TBL] [Abstract][Full Text] [Related]
17. In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38.
Huo X; Dunbar KB; Zhang X; Zhang Q; Spechler SJ; Souza RF
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G464-G478. PubMed ID: 31984785
[TBL] [Abstract][Full Text] [Related]
18. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus.
O'Connell K; Velanovich V
Surg Endosc; 2011 Mar; 25(3):830-4. PubMed ID: 20676687
[TBL] [Abstract][Full Text] [Related]
19. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery of zinc to Barrett's metaplasia by oral administration to Barrett's esophagus patients.
Valenzano MC; Mercado JM; Wang X; Zurbach EP; Raines J; McDonnell E; Morgan M; Farrell C; Rudolph D; Hwang A; Barr M; Cherian D; Bailey R; Raile B; Albert N; Thornton J; Zitin M; Abramson J; Newman G; Daum G; Mercogliano G; Mullin JM
Ther Deliv; 2014 Mar; 5(3):257-64. PubMed ID: 24592952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
